 |
|
HER-2 positivity is a high risk of recurrence of stage I gastric cancer
Seonhoo Kim, Yeon-Ji Kim, Woo Chul Chung
Korean J Intern Med. 2021;36(6):1327-1337. Published online 2021 Aug 26 DOI: https://doi.org/10.3904/kjim.2020.243
|
|
Citations to this article as recorded by
 Chinese national clinical practice guidelines on the prevention, diagnosis, and treatment of early gastric cancer
Peng Li, Ziyu Li, Enqiang Linghu, Jiafu Ji
Chinese Medical Journal.2024; 137(8): 887. CrossRef Clinical Pathological and Immunohistochemical Correlations in Gastric Cancer
Mihaela Andronic, Dragoș-Viorel Scripcariu, Mădălina Maria Palaghia, Ana-Maria Trofin, Valentin Bejan, Viorel Scripcariu
Diagnostics.2024; 14(13): 1367. CrossRef Clinicopathologic significance of Her-2 and P53 expressions in gastric cancer
Xiaoyu Zhang, Mingchuan Wang, Yizhuo Wang, Xianbin Cheng, Yang Jiang, Huijie Xiao
Asian Journal of Surgery.2023; 46(1): 526. CrossRef Downregulated Reprimo by LINC00467 participates in the growth and metastasis of gastric cancer
Yuanyuan Wu, Juan Du
Bioengineered.2022; 13(5): 11893. CrossRef Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo
Haiqiang Zhang, Xueshuai Ye, Junye Wen, Ziqi Cai, Yang Li, Mengya Zhang, Li Shen, Jianhui Cai
Scientific Reports.2022;[Epub] CrossRef Tumor Characteristics Associated with Lymph Node Metastasis and Prognosis in Patients with ERBB2-Positive Gastric Cancer
Ran Xu, Yisheng Zhang, Jun Zhao, Ke Chen, Zhengguang Wang, Ashok Pandurangan
Journal of Oncology.2022; 2022: 1. CrossRef
|